Related Experiment Videos
Effects of dilevalol and propranolol on hemodynamics in patients with essential hypertension
1First Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan.
Insights
Dilevalol significantly reduced blood pressure in hypertensive patients, unlike propranolol. Further research is needed to investigate dilevalol
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential hypertension is a widespread cardiovascular condition.
- Beta-blockers are commonly used to manage hypertension.
- Dilevalol is a novel beta-adrenergic blocking agent.
Purpose of the Study:
- To compare the efficacy and hemodynamic effects of dilevalol versus propranolol in patients with essential hypertension.
- To assess the safety profile of dilevalol, particularly regarding hepatotoxicity.
Main Methods:
- A randomized trial involving 18 patients with essential hypertension.
- Patients received either dilevalol (50-200 mg/day) or propranolol (60-90 mg/day) for six weeks.
- Hemodynamic parameters including mean arterial blood pressure, venous pressure, cardiac index, systemic vascular resistance, and heart rate were monitored.
Main Results:
- Dilevalol significantly reduced mean arterial blood pressure and venous pressure.
- Propranolol did not significantly alter these blood pressure parameters.
- Dilevalol maintained stable cardiac index and systemic vascular resistance, while propranolol reduced cardiac index and increased systemic vascular resistance.
- Heart rate remained unchanged in both groups.
Conclusions:
- Dilevalol demonstrates promising antihypertensive effects with favorable hemodynamic profiles.
- Further investigation is crucial to elucidate the mechanisms behind rare cases of fatal hepatotoxicity associated with dilevalol.
Abstract:
Eighteen patients with essential hypertension received 50 to 200 mg of dilevalol or 60 to 90 mg of propranolol daily for six weeks. Mean arterial blood pressure and venous pressure were significantly reduced in the dilevalol-treated patients at six weeks but were unchanged in the propranolol-treated patients. The cardiac index and systemic vascular resistance remained unchanged in the dilevalol group, but were significantly reduced (cardiac index) or increased (systemic vascular resistance) in the propranolol group. No changes in heart rate were noted in either treatment group. It is concluded that dilevalol has some ideal features for the treatment of hypertension, but further research is needed to determine the causes of fatal hepatotoxicity reported in a few cases.